Please login to the form below

Not currently logged in

Pfizer partners with hospital to research medicines for children

Children’s Hospital of Philadelphia joins CTI translational research network

Children's Hospital of Philadelphia

Pfizer has teamed up with the Children's Hospital of Philadelphia (CHOP) to research new treatments for use in children.

The CHOP becomes the second paediatric centre to join Pfizer's Centers for Therapeutic Innovation (CTI) network, a translational research unit that aims to partner Pfizer scientists with academic researchers to bring investigational products to market more quickly.

As with other projects in the CTI, scientists from both Pfizer and CHOP will work together to identify preclinical research at the hospital that has potential to one day be a treatment.

Once identified, Pfizer said it will share with CHOP researchers its library of antibodies and other proteins, as well as its R&D tools. 

CHOP has already discussed the prospect with its researchers, and hopes to have the first proposals submitted by April 15.

In July 2013, a steering committee will then select which projects will receive fundraising, with the ultimate aim of advancing a paediatric project into a phase I clinical trial.

The steering committee for this includes Dr Philip Johnson, chief scientific officer and senior vice president of The Children's Hospital of Philadelphia, who welcomed the partnership.

He said: “We are excited to have this opportunity to accelerate the process of moving scientific insights toward therapies that healthcare providers can offer in the clinic”

The Massachusetts-headquartered CTI was launched as an open innovation network by Pfizer in 2010, offering external investigators access to relevant Pfizer compounds and technologies.

The first programme was a partnership between Pfizer and the University of California, San Francisco (UCSF), with the pharma company providing $85m of funding.

Including the partnership with CHOP, for which financial details were not released, there are now 21 academic medical institutions working with Pfizer as part of the CTI, such as Rockefeller University, Beth Israel Deaconess Medical Center and the University of California's San Diego Health Sciences.

Each deal is different, although Pfizer says the model creates “significant financial opportunities through milestones and royalties” for the academic institutions.

4th April 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...